Evotec, Ionix develop compounds to inhibit CNS target
Executive Summary
Evotec (combinatorial chemistry) and Ionix Pharmaceuticals (analgesic drugs) will team up on the discovery of possible inhibitors of an Ionix sodium channel drug target that is expressed in the peripheral nervous system. Ionix will own, develop, and sell any resulting compounds to treat chronic inflammatory and neuropathic pain.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Alliance
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice